Indivior (INDV) said Wednesday that the US Food and Drug Administration has delayed its decision on the marketing application for label changes to Sublocade Injection.
Indivior said the FDA has no outstanding issues to address, adding that the company will provide additional updates on the approval status of the proposed label changes as needed.